SEMLER SCIENTIFIC, INC. (OTCMKTS:SMLR) Files An 8-K Results of Operations and Financial Condition

19

SEMLER SCIENTIFIC, INC. (OTCMKTS:SMLR) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

On August 2, 2017, Semler Scientific, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2017. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

The information contained in this Item 9.01 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

(d) Exhibits.

Exhibit No.

Description

99.1 Press Release of Semler Scientific, Inc., dated August 2, 2017.


Semler Scientific, Inc. Exhibit
EX-99.1 2 t1702278_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1     Semler Reports Second Quarter and First Half 2017 Financial Results   Strong Revenue Growth Driven By Increasing Number of Installations   PORTLAND,…
To view the full exhibit click here

About SEMLER SCIENTIFIC, INC. (OTCMKTS:SMLR)

Semler Scientific, Inc. develops, manufactures and markets products and services that assist healthcare insurers and physician groups in evaluating and treating chronic diseases. The Company markets QuantaFlo and WellChec to its customers. QuantaFlo is an approximately four-minute in-office blood flow test. The routine office usage of the QuantaFlo has ranges from few tests per week to over 10 tests per day. The Company also offers contracts in which it invoices on a per test basis for use of QuantaFlo, or as part of the WellChec multi-test platform. WellChec is the Company’s multi-test service platform. WellChec provides testing equipment and third-party personnel to perform tests and examinations of patients for the Company’s customers. The tests performed are for chronic disease states, which include respiratory disease, vascular disease, eye disease, bone disease, heart disease, neuropathy and diabetes.

An ad to help with our costs